- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary mediastinal B-cell lymphoma (PMBCL)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Pembrolizumab – March 2020
Pembrolizumab (PMBCL): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
Last updated
3 July 2020